Skip to main content
. 2020 Oct 5;40(12):694–710. doi: 10.1002/cac2.12103

FIGURE 6.

FIGURE 6

SCH23390 plays a tumor‐suppressive role both in vitro and in vivo. (A) Cell viability assay in HCC cell lines, hepatoblastoma Hep‐G2, and Miha cells after treatment with SCH23390 (100 µM, a selective DRD1 antagonist). (B) Migration and invasion of MHCC‐97H and SK‐Hep‐1 cells after treatment with SCH23390. (C) SCH23390 (0.1 mg/kg) restrained tumor growth (compared with the control) in the xenograft tumor model. The data are presented as the mean ± SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Abbreviations: DRD1, dopamine receptor D1. HCC, hepatocellular carcinoma.